HER2 alteration is a rare but widely acknowledged oncogenic driver of non‐small cell lung cancer (NSCLC), which includes HER2 overexpression, amplification, and gene mutation with incidence rates of 7.7%–23%, 2%–22%, and 1%–6.7%, respectively [1]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.